10-Q: RadNet Q1 2026: Revenue Up, Net Loss Widens Amid Acquisitions

RadNet reports a significant increase in total service revenue for Q1 2026, driven by its Imaging Centers segment, but a wider net loss attributable to increased operating expenses and strategic acquisitions.

Summary

• RadNet reported total service revenue of $575.6 million for the three months ended March 31, 2026, a 22.1% increase compared to $471.4 million in the same period of 2025.
• The Imaging Centers segment saw a 20.7% increase in revenue to $556.8 million, with same-center revenue growing by 8.9%.
• The Digital Health segment revenue grew by 51.5% to $29.1 million, driven by AI-related revenue and acquisitions.
• Despite revenue growth, the company reported a net loss attributable to RadNet, Inc. common stockholders of $33.5 million for Q1 2026, compared to a net loss of $37.9 million in Q1 2025.
• Operating expenses increased significantly, particularly in the Digital Health segment, due to acquisitions and integration costs.
• The company completed several acquisitions, including Gleamer SAS for approximately $264.1 million, and Regional Radiology Center and Northwest Radiology Network PC for $67.3 million combined.
• Cash and cash equivalents decreased to $455.3 million from $767.2 million at the end of 2025, largely due to investing activities related to acquisitions.
• Adjusted EBITDA for the total company increased to $63.3 million from $46.4 million in the prior year period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with strong revenue growth and improved Adjusted EBITDA, but tempered by a continued net loss and significant investment in future growth areas.

Positives

• Total service revenue increased by 22.1% to $575.6 million in Q1 2026 compared to Q1 2025.
• Imaging Centers segment revenue grew by 20.7% to $556.8 million, with same-center revenue up 8.9%.
• Digital Health segment revenue surged by 51.5% to $29.1 million, indicating strong growth in AI and enterprise informatics.
• Systemwide procedural volumes increased by 10.1% overall, with significant growth in PET/CT (35.2%) and MRI (20.3%).
• Adjusted EBITDA for the total company increased by 36.4% to $63.3 million.
• The company successfully integrated iCAD, Inc. and SeeMode Technologies into the Digital Health segment.
• Acquisition of Gleamer SAS is expected to enhance AI capabilities and expand global market presence.

Negatives

• Net loss attributable to RadNet, Inc. common stockholders was $33.5 million for Q1 2026, a slight improvement from $37.9 million in Q1 2025, but still a significant loss.
• Total operating expenses increased by 17.5% to $563.0 million.
• The Digital Health segment reported a loss from operations of $17.7 million, a significant increase from $6.1 million in the prior year.
• Cash and cash equivalents decreased by $311.9 million, primarily due to investing activities related to acquisitions.
• Accounts receivable increased to $209.1 million from $200.3 million.
• Working capital (exclusive of current operating lease liabilities) decreased significantly to $171.7 million from $507.3 million.

Risks

• The company is exposed to foreign exchange risk with respect to revenues and expenses denominated in Pound Sterling, Euro, Canadian Dollar, Hungarian Forint, and Indian Rupee.
• Debt instruments bear interest at variable rates, making the company susceptible to changes in short-term interest rates.
• The outcome of pending legal proceedings is uncertain and could materially adversely affect results if resolved against the company.
• The company's business is subject to risks and uncertainties described in its Annual Report, including those related to acquisitions, integration, competition, and regulatory changes.
• The Digital Health segment is expected to continue operating at a net loss in the near term due to ongoing integration of recent acquisitions.

Future Outlook

The company expects its existing capital resources, anticipated cash from operations, and borrowing capacity to be sufficient for the next twelve months and the foreseeable future. Future acquisitions are expected to be funded primarily through cash flow from operations and borrowings.

Management Comments

• The company's multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes, and provides patients and referring physicians one location for multiple procedures.
• The Digital Health segment aims to enhance interpretation of medical images and improve patient outcomes through AI-powered health informatics.
• The company expects the Digital Health segment to continue operating at a net loss in the near term as integration of recent acquisitions progresses.
• Management believes that payor diversity mitigates exposure to unfavorable reimbursement trends within any one payor class.
• The company generally experiences the lowest volumes of procedures and revenue during the first quarter due to winter weather and patient high-deductible health plan resets.

Industry Context

StockSavvy.ai notes that RadNet's Q1 2026 results reflect continued industry trends of consolidation in diagnostic imaging and significant investment in digital health and AI solutions to improve efficiency and outcomes. The company's strategic acquisitions, particularly in the AI space, align with broader healthcare technology advancements.

Comparison to Industry Standards

• RadNet's same-center revenue growth of 8.9% in its Imaging Centers segment for Q1 2026 is a solid performance, indicating healthy organic growth in a competitive market.
• The significant revenue increase in the Digital Health segment (51.5%) outpaces many pure-play AI healthcare companies, suggesting successful integration and market penetration.
• The company's net loss, while substantial, is a common characteristic for companies undergoing aggressive acquisition and integration phases, especially in rapidly evolving sectors like AI in healthcare.
• The increase in Adjusted EBITDA by 36.4% demonstrates effective operational leverage and cost management within the core imaging business, despite increased investment in growth areas.

Legal Proceedings

• The company is party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business.
• Management does not believe that the outcome of any current legal proceedings will have a material adverse impact on the business, financial condition, or results of operations.

Related Party Transactions

• Management service fees charged from imaging centers underlying unconsolidated joint ventures amounted to $6.6 million for Q1 2026.
• Amounts transacted between RadNet and unconsolidated joint ventures are in the ordinary course of business and disclosed in due from/to affiliate accounts.
• A $17.0 million promissory note was executed with Dignity Health (a related party and joint venture member) on June 12, 2025, with a remaining balance of $8.6 million classified as current at March 31, 2026.

Stakeholder Impact

• Shareholders: Continued net losses may impact investor sentiment, but revenue growth and improved EBITDA suggest underlying business strength.
• Employees: Increased staffing in Imaging Centers to support volume growth; potential integration challenges and opportunities in Digital Health segment.
• Customers: Continued expansion of imaging center network and AI solutions may offer improved access and diagnostic capabilities.
• Creditors: Company remains compliant with credit facility covenants, indicating stability in debt servicing.

Next Steps

• Continue integration of acquired companies (CIMAR UK and Gleamer SAS).
• Monitor and manage operating expenses, particularly in the Digital Health segment.
• Evaluate future transactions, including acquisitions, divestitures, and joint ventures.
• Continue to develop and deploy AI products and solutions within the Digital Health segment.
• Manage debt obligations and credit facilities.

Key Dates

Recommendation

RadNet demonstrates strong revenue growth and operational improvements in its core imaging business, evidenced by increased Adjusted EBITDA. However, the persistent net loss, significant investment in the Digital Health segment which is currently unprofitable, and the substantial cash outflow for acquisitions warrant a cautious 'hold' recommendation. Investors should monitor the successful integration of recent acquisitions and the path to profitability for the Digital Health segment.

Keywords

RadNet, 10-Q, Quarterly Report, Diagnostic Imaging, Digital Health, Artificial Intelligence, Acquisitions, Revenue, Net Loss, EBITDA, Financial Statements, SEC Filing